Please login to the form below

Not currently logged in
Email:
Password:

Douglas Williams named president and CEO of Codiak

He joins from Biogen wherehe was executive VP of research and development

Codiak BioSciences Biogen Douglas WilliamsBiogen's former executive VP of research and development Douglas Williams has joined a new Cambridge, US-based start-up company.

He has been appointed president and CEO of Codiak BioSciences, which will focus on developing exosomes - cell-derived delivery systems - for the treatment of a wide array of diseases, including cancer.

Williams said: “I look forward to building a world-class team to harness the power of exosomes for therapeutic and diagnostic purposes. We seek to grow Codiak into the leader in this emerging field as we strive to make new, breakthrough medicines that provide significant and lasting patient benefit.”

He served at Biogen from January 2011 to July 2015, joining that firm from ZymoGenetics, where he was CEO and a member of the board of directors.

During Williams' tenure at ZymoGenetics the US biotech was acquired by Bristol-Myers Squibb for $985m and prior to his time there he held several leadership positions within the biotechnology industry.

These included serving as chief scientific officer and executive vice president of research and development at Seattle Genetics and as senior vice president and Washington site leader at Amgen.

Williams also served in a series of scientific and senior leadership positions for more than a decade at Immunex Corp.

20th November 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Patient Involvement in Health Technology Assessment
Exploring the evolution of patient involvement in health technology assessment (HTA), and the role of the patient voice in market access....

Infographics